Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals
Kawana-Tachikawa, Ai (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Llibre, Josep M.. (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Bravo, Isabel (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Escrig, Roser (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Mothe, Beatriz (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Puig, Jordi (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Puertas, Maria C. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Martinez-Picado, Javier (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Blanco, Julià (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Manzardo, Christian (Hospital Clínic i Provincial de Barcelona)
Miro, Jose M. (Hospital Clínic i Provincial de Barcelona)
Iwamoto, Aikichi (The Institute of Medical Science, The University of Tokyo, Japan)
Pozniak, Anton L. (HIV/GUM Department, Chelsea and Westminster Hospital, London, United Kingdom)
Gatell, Jose M. (Hospital Clínic i Provincial de Barcelona)
Clotet Sala, Bonaventura (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Brander, Christian (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Universitat Autònoma de Barcelona. Departament de Medicina

Date:	2014
Abstract:	The effect of maraviroc on the maintenance and the function of HIV-1-specific T cell responses remains unknown. Subjects recently infected with HIV-1 were randomized to receive anti-retroviral treatment with or without maraviroc intensification for 48 weeks, and were monitored up to week 60. PBMC and in vitro -expanded T cells were tested for responses to the entire HIV proteome by ELISpot analyses. Intracellular cytokine staining assays were conducted to monitor the (poly)-functionality of HIV-1-specific T cells. Analyses were performed at baseline and week 24 after treatment start, and at week 60 (3 months after maraviroc discontinuation). Maraviroc intensification was associated with a slower decay of virus-specific T cell responses over time compared to the non-intensified regimen in both direct ex-vivo as well as in in-vitro expanded cells. The effector function profiles of virus-specific CD8 + T cells were indistinguishable between the two arms and did not change over time between the groups. Maraviroc did not negatively impact any of the measured parameters, but was rather associated with a prolonged maintenance of HIV-1-specific T cell responses. Maraviroc, in addition to its original effect as viral entry inhibitor, may provide an additional benefit on the maintenance of virus-specific T cells which may be especially important for future viral eradication strategies.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	PloS one, Vol. 9 (january 2014) , ISSN 1932-6203

DOI: 10.1371/journal.pone.0087334
PMID: 24475275

11 p, 844.7 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Neurociències (INc)
Articles > Research articles
Articles > Published articles